JP NIID Weekly
Japan weekly infectious disease surveillance via NIID/JIHS.
Decision brief
Weekly reportJapan
Japan Infectious Disease Decision Brief | 2025-05-30 to 2026-05-30
Executive summary
Current Situation
This report covers 86 disease signals with 4,178,290 cases and 27,006 cases in the latest observation. The lead signal is Hepatitis A. The current source does not provide death-count fields, so missing values should not be interpreted as absence of mortality burden.
Decision brief
Current judgement and next actions
Cases
4,178,290
Latest cases
27,006
Death scope
Deaths not reported
Data confidence
70%
This report covers 86 disease signals with 4,178,290 cases and 27,006 cases in the latest observation. The lead signal is Hepatitis A. The current source does not provide death-count fields, so missing values should not be interpreted as absence of mortality burden.
- →The evidence packet contains 4,178,290 cases, including 27,006 in the latest observation.
- →The lead signal is Hepatitis A; active review is recommended before escalation.
- →The current source does not provide death-count fields, so missing values should not be interpreted as absence of mortality burden.
Table of contents
Disease table of contents
Snapshot
Shown86/86
High attention+4
Rising34
The 0–100 surveillance attention score only orders signal review. It combines reported burden, change, mortality signals when available, anomaly markers, historical position, and data quality; it is uncalibrated and is not infection, severity, mortality, or outbreak risk.
| # | Disease | Attention band | Cases (MoM) | Period cases | YTD cumulative | YoY |
|---|---|---|---|---|---|---|
| 1 | D007Viral | high63 | 11+175% | 137 | 224 2026 YTD | +267% |
| 2 | D028Bacterial | high62 | 133+241% | 59,192 | 3,583 2026 YTD | -94% |
| 3 | D118Bacterial | high62 | 20+233% | 64 | 0 YTD cumulative | 0.0% |
| 4 | D139Viral | high61 | 331+149% | 49,947 | 38,796 2026 YTD | +15% |
| 5 | D048Viral | moderate56 | 1,477+85% | 30,415 | 151,470 2026 YTD | +294% |
| 6 | D119Bacterial | moderate52 | 6,828+88% | 270,350 | 0 YTD cumulative | -0.5% |
| 7 | D110Bacterial | moderate50 | 5+400% | 67 | 39 2026 YTD | +25% |
| 8 | D025Bacterial | moderate48 | 254+137% | 11,378 | 8,014 2026 YTD | +18% |
| 9 | D133Bacterial | moderate48 | 15+67% | 316 | 0 YTD cumulative | 0.0% |
| 10 | D034Bacterial | moderate47 | 147+86% | 8,121 | 5,329 2026 YTD | -33% |
| 11 | D141Viral | moderate46 | 974+66% | 40,691 | 25,696 2026 YTD | -37% |
| 12 | D138Viral | moderate46 | 196+63% | 109,457 | 8,264 2026 YTD | -96% |
| 13 | D047Bacterial | moderate45 | 11,317+62% | 608,034 | 414,004 2026 YTD | -26% |
| 14 | D143Viral | moderate44 | 823+52% | 31,908 | 21,196 2026 YTD | -7.7% |
| 15 | D115Bacterial | moderate42 | 65+171% | 4,059 | 2,528 2026 YTD | +71% |
| 16 | D024Bacterial | moderate42 | 7+250% | 172 | 0 YTD cumulative | +600% |
| 17 | D011Viral | moderate40 | 10+150% | 524 | 398 2026 YTD | +25% |
| 18 | D137Viral | moderate38 | 358+43% | 23,981 | 10,695 2026 YTD | -32% |
| 19 | D054Viral | moderate37 | 1,095+25% | 39,153 | 26,764 2026 YTD | -21% |
| 20 | D004Viral | moderate35 | 1,395+10% | 510,443 | 161,446 2026 YTD | -57% |
| 21 | D100Bacterial | moderate35 | 16+60% | 420 | 318 2026 YTD | +45% |
| 22 | D142Viral | low34 | 633+2.9% | 85,368 | 39,389 2026 YTD | +2.3% |
| 23 | D005Viral | low34 | 15+150% | 591 | 470 2026 YTD | +50% |
| 24 | D136Bacterial | low34 | 7+75% | 214 | 191 2026 YTD | +75% |
| 25 | D038Viral | low33 | 527-20% | 2,262,135 | 1,040,687 2026 YTD | -69% |
| 26 | D017Viral | low33 | 17-5.6% | 573 | 500 2026 YTD | +1600% |
| 27 | D065Viral | low31 | 5+67% | 74 | 107 2026 YTD | 0.0% |
| 28 | D039Viral | low30 | 84+35% | 5,090 | 2,752 2026 YTD | -62% |
| 29 | D140Bacterial | low29 | 75-7.4% | 17,868 | 4,802 2026 YTD | -56% |
| 30 | D057Viral | low29 | 10+11% | 183 | 130 2026 YTD | -17% |
| 31 | D106Bacterial | low27 | 66+3.1% | 2,117 | 1,504 2026 YTD | +35% |
| 32 | D021Viral | low27 | 2+100% | 126 | 75 2026 YTD | +100% |
| 33 | D135Bacterial | low25 | 10+25% | 417 | 301 2026 YTD | 0.0% |
| 34 | D125Bacterial | low24 | 3+50% | 66 | 39 2026 YTD | 0.0% |
| 35 | D107Bacterial | low21 | 38+8.6% | 2,065 | 1,497 2026 YTD | -30% |
| 36 | D134Viral | low21 | 13+18% | 1,026 | 615 2026 YTD | -38% |
| 37 | D058Bacterial | low20 | 3+50% | 240 | 56 2026 YTD | -40% |
| 38 | D041Viral | low17 | 8+14% | 473 | 221 2026 YTD | -71% |
| 39 | D089Viral | low15 | 6-33% | 157 | 0 YTD cumulative | 0.0% |
| 40 | D120Bacterial | low14 | 20.0% | 74 | 49 2026 YTD | 0.0% |
| 41 | D020Viral | low14 | 00.0% | 6 | 2 2026 YTD | 0.0% |
| 42 | D045Parasitic | low12 | 00.0% | 11 | 10 2026 YTD | 0.0% |
| 43 | D037Parasitic | low9 | 00.0% | 21 | 28 2026 YTD | 0.0% |
| 44 | D144Prion | low8 | 10.0% | 121 | 76 2026 YTD | 0.0% |
| 45 | D052Viral | low8 | 10.0% | 15 | 4 2026 YTD | 0.0% |
| 46 | D006Viral | low7 | 30.0% | 131 | 87 2026 YTD | -50% |
| 47 | D146Fungal | low7 | 00.0% | 122 | 79 2026 YTD | -100% |
| 48 | D013Viral | low7 | 00.0% | 8 | 0 2026 YTD | 0.0% |
| 49 | D095Fungal | low6 | 00.0% | 6 | 5 2026 YTD | 0.0% |
| 50 | D099Parasitic | low5 | 00.0% | 25 | 23 2026 YTD | 0.0% |
| 51 | D032Bacterial | low5 | 00.0% | 2 | 1 2026 YTD | 0.0% |
| 52 | D002Bacterial | low5 | 00.0% | 1 | 1 2026 YTD | 0.0% |
| 53 | D051Viral | low5 | 00.0% | 1 | 0 2026 YTD | 0.0% |
| 54 | D145Bacterial | low5 | 00.0% | 1 | 3 2026 YTD | -100% |
| 55 | D001Bacterial | low5 | 00.0% | 0 | 0 2026 YTD | 0.0% |
| 56 | D003Viral | low5 | 00.0% | 0 | 0 2026 YTD | 0.0% |
| 57 | D014Viral | low5 | 00.0% | 0 | 0 2026 YTD | 0.0% |
| 58 | D015Viral | low5 | 00.0% | 0 | 0 2026 YTD | 0.0% |
| 59 | D016Viral | low5 | 00.0% | 0 | 0 2026 YTD | 0.0% |
| 60 | D018Viral | low5 | 00.0% | 0 | 0 2026 YTD | 0.0% |
| 61 | D019Viral | low5 | 00.0% | 0 | 0 2026 YTD | 0.0% |
| 62 | D023Bacterial | low5 | 00.0% | 0 | 0 2026 YTD | 0.0% |
| 63 | D029Bacterial | low5 | 00.0% | 0 | 0 2026 YTD | 0.0% |
| 64 | D043Bacterial | low5 | 00.0% | 0 | 0 YTD cumulative | 0.0% |
| 65 | D049Viral | low5 | 00.0% | 0 | 0 2026 YTD | 0.0% |
| 66 | D050Viral | low5 | 00.0% | 0 | 0 2026 YTD | 0.0% |
| 67 | D053Viral | low5 | 00.0% | 0 | 0 2026 YTD | 0.0% |
| 68 | D059Viral | low5 | 00.0% | 0 | 0 2026 YTD | 0.0% |
| 69 | D062Viral | low5 | 00.0% | 0 | 0 YTD cumulative | 0.0% |
| 70 | D064Other | low5 | 00.0% | 0 | 0 2026 YTD | 0.0% |
| 71 | D075Other | low5 | 00.0% | 0 | 0 YTD cumulative | 0.0% |
| 72 | D091Bacterial | low5 | 00.0% | 0 | 0 2026 YTD | 0.0% |
| 73 | D102Viral | low5 | 00.0% | 0 | 0 YTD cumulative | 0.0% |
| 74 | D113Bacterial | low5 | 00.0% | 0 | 0 2026 YTD | 0.0% |
| 75 | D123Bacterial | low5 | 00.0% | 0 | 0 2026 YTD | 0.0% |
| 76 | D127Viral | low5 | 00.0% | 0 | 0 YTD cumulative | 0.0% |
| 77 | D128Viral | low5 | 00.0% | 0 | 0 2026 YTD | 0.0% |
| 78 | D116Bacterial | low5 | 00.0% | 0 | 1 2026 YTD | 0.0% |
| 79 | D132Bacterial | low5 | 00.0% | 0 | 0 2026 YTD | 0.0% |
| 80 | D035Bacterial | low4 | 00.0% | 58 | 5 2026 YTD | 0.0% |
| 81 | D109Bacterial | low4 | 00.0% | 14 | 3 2026 YTD | 0.0% |
| 82 | D096Parasitic | low4 | 00.0% | 13 | 6 2026 YTD | -100% |
| 83 | D112Bacterial | low4 | 00.0% | 8 | 4 2026 YTD | -100% |
| 84 | D026Bacterial | low3 | 00.0% | 7 | 0 YTD cumulative | 0.0% |
| 85 | D124Bacterial | low2 | 0-100% | 28 | 22 2026 YTD | 0.0% |
| 86 | D040Viral | low0 | 00.0% | 5 | 3 2026 YTD | 0.0% |
Current judgement
Current Judgement
- Current judgement: Japan should treat Hepatitis A as the lead signal for active review.
- Scope: 86 disease signals and 4,178,290 cases are included.
- Death-count scope: The current source does not provide death-count fields, so missing values should not be interpreted as absence of mortality burden.
Priority actions
Priority Actions
- Active review: confirm whether Hepatitis A is persistent and concentrated by place or population group.
- Add stratification: prioritize place, age group, reporting source, and testing scope before escalation.
- Escalate when: repeated increases, severity signals, or external event reports corroborate the signal.
- Death data: The current source does not provide death-count fields, so missing values should not be interpreted as absence of mortality burden.
Signal evidence
Signal Evidence
- The latest observation contains 27,006 cases.
- Hepatitis A: 11 latest cases, high priority.
- Pertussis: 133 latest cases, high priority.
- Spotted fever rickettsiosis: 20 latest cases, high priority.
- Herpangina: 331 latest cases, high priority.
- Hand-Foot-Mouth Disease: 1,477 latest cases, moderate priority.
Disease context
Disease Context
- Plague: 0 cumulative cases; interpret with transmission route, seasonality, and risk groups.
- Cholera: 1 cumulative cases; interpret with transmission route, seasonality, and risk groups.
- SARS: 0 cumulative cases; interpret with transmission route, seasonality, and risk groups.
- COVID-19: 510,443 cumulative cases; interpret with transmission route, seasonality, and risk groups.
- HIV/AIDS: 591 cumulative cases; interpret with transmission route, seasonality, and risk groups.
Data notes
Data Notes
- Data confidence: medium, quality score 0.7.
- Case scope: sentinel surveillance; rate basis: unavailable.
- Death-count scope: The current source does not provide death-count fields, so missing values should not be interpreted as absence of mortality burden.
- Interpretation limit: increasing cases do not confirm an outbreak without testing volume, reporting lag, and stratified distribution review.
Download Underlying Dataset
Download the country dataset used to generate this report, including source metadata.
Official sourcesAuthority, cadence, notes1